Targeting potent warheads to the tumour microenvironment

Our Science

The pre|CISION™ peptide drug conjugate platform. >

Partnering

Avacta is seeking to expand its partnerships for targeted cancer therapies. >

Investors

Growing shareholder value by developing novel cancer therapies using our proprietary pre|CISION™ and Affimer® platforms. >

 

AVA6000 is the first clinical-stage pre|CISIONTM molecule. It is a peptide drug conjugate that leverages the tumour-specific expression of FAP.

Read more

Latest news

| Investors

Latest news

| Investors